GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...

The clinical trial success of bepirovirsen, which will be submitted to regulatory agencies for approval, could be a boon for ...

AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) is one of the largest pharmaceutical companies in the world. The firm scored ...

GSK (GSK) and other leading drugmakers plans to raise prices of as many as 350 medicines next year, with a median hike of ...

A type 1 diabetes drug under development by GlaxoSmithKline has failed in late stage clinical trials. GSK (NYSE:GSK) announced Friday that otelixizumab, an investigational compound for type 1 diabetes ...

British pharmaceutical giant GlaxoSmithKline will stop paying physicians to speak about its drugs and linking sales representatives’ pay to how many prescriptions physicians write, according to a Wall ...